- Global Pharma News & Resources

Fagron NV: Disclosure of received notification

Regulated information
Nazareth (Belgium)/Rotterdam (the Netherlands), 31 August 2018

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notification.

Notification of Adrianus van Herk, received on 28 August 2018

  • On 28 August 2018, Fagron received a notification that the shareholding of Adrianus van Herk, a person that notifies alone, had fallen below the disclosure threshold of 3% on 27 August 2018 as the result of the disposal of voting securities or voting rights.
  • The notification of Adrianus van Herk can be viewed on via this link .

In case of differences between the English translation and the Dutch original of this press release, the latter will prevail.

For more information
Constantijn van Rietschoten
Chief Communications Officer
Tel. +31 6 53 69 15 85

Fagron profile
Fagron is a leading global company active in pharmaceutical compounding and focused on delivering personalized pharmaceutical care to hospitals, pharmacies, clinics and patients in 35 countries worldwide.

The Belgian company Fagron NV is located in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam (stock market code 'FAGR'). The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

Disclosure of received notification

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Fagron NV via GlobeNewswire

Editor Details

Last Updated: 01-Sep-2018